Synthetic lethal screens identify vulnerabilities in GPCR signaling and cytoskeletal organization in e-cadherin-deficient cells

Molecular Cancer Therapeutics

Volumn 14, Issue 5, 2015, Pages 1213-1223

  Telford, Bryony J ^a   Chen, Augustine ^a   Beetham, Henry ^a   Frick, James ^a   Brew, Tom P ^a   Gould, Cathryn M ^b,d   Single, Andrew ^a   Godwin, Tanis ^a   Simpson, Kaylene J ^b,c   Guilford, Parry ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; ALISERTIB; AURORA KINASE INHIBITOR; AZD 8055; BREFELDIN A; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; CRIZOTINIB; CYTOSKELETON PROTEIN; DACINOSTAT; DANUSERTIB; ENTINOSTAT; G PROTEIN COUPLED RECEPTOR; GANDOTINIB; JNJ 7706621; MOCETINOSTAT; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OBATOCLAX; OMIPALISIB; PANOBINOSTAT; PERTUSSIS TOXIN; PRACINOSTAT; PROTEIN TYROSINE KINASE INHIBITOR; QUISINOSTAT; SARACATINIB; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TYRPHOSTIN A9; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VORINOSTAT; AZEPINE DERIVATIVE; BENZAMIDE DERIVATIVE; CADHERIN; CDH1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; BREAST CELL; CELL ADHESION; CELL FUNCTION; CELL LINE; CONTROLLED STUDY; CYTOSKELETON; DRUG MECHANISM; DRUG SCREENING; GENE EXPRESSION; GENE LOSS; GENE ONTOLOGY; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LENTIVIRINAE; LETHALITY; MEDIATOR; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; DEFICIENCY; DRUG DEVELOPMENT; DRUG EFFECTS; FEMALE; GENETICS; STOMACH NEOPLASMS; TUMOR CELL LINE;

AZEPINES; BENZAMIDES; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; DRUG DISCOVERY; FEMALE; HUMANS; IMIDAZOLES; PERTUSSIS TOXIN; PYRAZOLES; PYRIDAZINES; PYRIMIDINES; RECEPTORS, G-PROTEIN-COUPLED; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84942122654     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-1092     Document Type: Article

References (49)

1. Berx G, van Roy F. Involvement ofmembers of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009;1:a003129.
2. Mohamet L, Hawkins K, Ward CM. Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis. J Oncol 2011;2011:352616.
3. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008;27:6920-9.
4. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-5.
5. Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B, Seruca R, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 2013;31:868-75.
6. Vlug E, Ercan C, van der Wall E, van Diest PJ, Derksen PW. Lobular breast cancer: pathology, biology, and options for clinical intervention. Arch Immunol Ther Exp 2013;62:7-21.
7. Chen A, BeethamH, Black MA, Priya R, Telford BJ, Guest J, et al. E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. BMC Cancer 2014;14:552.
8. Brieher WM, Yap AS. Cadherin junctions and their cytoskeleton (s). Curr Opin Cell Biol 2013;25:39-46.
9. den Elzen N, Buttery CV, Maddugoda MP, Ren G, Yap AS. Cadherin adhesion receptors orient the mitotic spindle during symmetric cell division in mammalian epithelia. Mol Biol Cell 2009;20:3740-50.
10. Zou D, Yoon HS, Perez D, Weeks RJ, Guilford P, Humar B. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. J Pathol 2009;218:265-72.
11. Humar B, Blair V, Charlton A, More H, Martin I, Guilford P. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res 2009;69:2050-6.
12. Humar B, Guilford P. Hereditary diffuse gastric cancer and lost cell polarity: a short path to cancer. Future Oncol (London, England) 2008;4:229-39.
13. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
14. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-9.
15. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.
16. Kamentsky L, Jones TR, Fraser A, Bray MA, Logan DJ, Madden KL, et al. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics 2011;27:1179-80.
17. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001;29:2002-7.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
19. Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ, et al. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell 2013;24:182-96.
20. Lee AS, Burdeinick-Kerr R, Whelan SP. A genome-wide small interfering RNA screen identifies host factors required for vesicular stomatitis virus infection. J Virol 2014;88:8355-60.
21. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
22. Garland P, Quraishe S, French P, O'Connor V. Expression of the MAST family of serine/threonine kinases. Brain Res 2008;1195:12-9.
23. Villarroel-Campos D, Gonzalez-Billault C. The MAP1B case: an old MAP that is new again. Dev Neurobiol 2014;74:953-71.
24. Akhmanova A, Steinmetz MO. Tracking the ends: a dynamic protein network controls the fate of microtubule tips. Nat Rev Mol Cell Biol 2008;9:309-22.
25. Clark MJ, Traynor JR. Assays forG-protein-coupled receptor signaling using RGS-insensitive Galpha subunits. Methods Enzymol 2004;389:155-69.
26. Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010;28 Suppl 1:S3-20.
27. Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Cancer Chemother Pharmacol 2010;66:1131-40.
28. Dietrich CS III, Greenberg VL, DeSimone CP, Modesitt SC, van Nagell JR, Craven R, et al. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol 2010;116:126-30.
29. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 2010;126:743-55.
30. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC, et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006;5:2767-76.
31. Ganguly S, Saxena R, Chattopadhyay A. Reorganization of the actin cytoskeleton upon G-protein coupled receptor signaling. BiochimBiophys Acta 2011;1808:1921-9.
32. Schappi JM, Krbanjevic A, Rasenick MM. Tubulin, actin and heterotrimeric G proteins: coordination of signaling and structure. Biochim Biophys Acta 2014;1838:674-81.
33. Saengsawang W, Rasenick MM. Heterotrimeric G proteins and microtubules. Methods Cell Biol 2013;115:173-89.
34. Kollman JM, Merdes A, Mourey L, Agard DA. Microtubule nucleation by gamma-tubulin complexes. Nat Rev Mol Cell Biol 2011;12:709-21.
35. Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev 2014;14:598-610.
36. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev 2009;28:5-14.
37. Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 2014;46:583-7.
38. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9.
39. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014;46:573-82.
40. Spiegelberg BD. G protein coupled-receptor signaling and reversible lysine acetylation. J Recept Signal Transduct Res 2013;33:261-6.
41. Schemies J, Sippl W, Jung M. Histone deacetylase inhibitors that target tubulin. Cancer Lett 2009;280:222-32.
42. Pelletier S, Duhamel F, Coulombe P, Popoff MR, Meloche S. Rho family GTPases are required for activation of Jak/STAT signaling by G proteincoupled receptors. Mol Cell Biol 2003;23:1316-33.
43. Hochegger H, Hegarat N, Pereira-Leal JB. Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle. Open Biol 2013;3:120185.
44. Luttrell LM, Hawes BE, van Biesen T, Luttrell DK, Lansing TJ, Lefkowitz RJ. Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation ofmitogen-activated protein kinases. J Biol Chem 1996;271:19443-50.
45. Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, et al. RAS and RH Of amilies of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 2013;153:1050-63.
46. Blair VR. Hereditary diffuse gastric cancer: Of mice and man. Auckland, New Zealand: PhD thesis, University of Auckland; 2008.
47. Petridis C, Shinomiya I, Kohut K, Gorman P, Caneppele M, Shah V, et al. Germline CDH1 mutations in bilateral lobular carcinoma in situ. Br J Cancer 2014;110:1053-7.
48. Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 2004;53:814-20.
49. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical managementand directions for future research. JMedGenet 2010;47:436-44.